{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:42:08Z","timestamp":1771832528291,"version":"3.50.1"},"reference-count":50,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA129154"],"award-info":[{"award-number":["R01 CA129154"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["PCF Movember Challenge Award"],"award-info":[{"award-number":["PCF Movember Challenge Award"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0516-1","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T13:03:43Z","timestamp":1548853423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["FLT PET\/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab"],"prefix":"10.1136","volume":"7","author":[{"given":"Matthew","family":"Scarpelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Zahm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas G.","family":"McNeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Jeraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-1911","authenticated-orcid":false,"given":"Glenn","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"516_CR1","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebb\u00e9 C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412\u201320.","journal-title":"Clin Cancer Res"},{"key":"516_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40425-016-0107-3","volume":"4","author":"J Yuan","year":"2016","unstructured":"Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer. 2016;4:3.","journal-title":"J Immunother Cancer"},{"key":"516_CR3","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1158\/1078-0432.CCR-13-3132","volume":"20","author":"JF Gainor","year":"2014","unstructured":"Gainor JF, Longo DL, Chabner BA. Pharmacodynamic biomarkers: falling short of the mark? Clin Cancer Res. 2014;20:2587\u201394.","journal-title":"Clin Cancer Res"},{"key":"516_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40425-017-0243-4","volume":"5","author":"S Gnjatic","year":"2017","unstructured":"Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, et al. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer. 2017;5:44.","journal-title":"J Immunother Cancer"},{"key":"516_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124\u20138.","journal-title":"Science"},{"key":"516_CR6","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189\u201399.","journal-title":"N Engl J Med"},{"key":"516_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40425-016-0178-1","volume":"4","author":"GV Masucci","year":"2016","unstructured":"Masucci GV, Cesano A, Hawtin R, Janetzki S, Zhang J, Kirsch I, Dobbin KK, Alvarez J, Robbins PB, Selvan SR, et al. Validation of biomarkers to predict response to immunotherapy in cancer: volume I - pre-analytical and analytical validation. J Immunother Cancer. 2016;4:76.","journal-title":"J Immunother Cancer"},{"key":"516_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/CJI.0b013e3181dda23e","volume":"33","author":"JT Becker","year":"2010","unstructured":"Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother. 2010;33:639\u201347.","journal-title":"J Immunother"},{"key":"516_CR9","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1158\/1078-0432.CCR-14-0169","volume":"20","author":"DG McNeel","year":"2014","unstructured":"McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, Staab MJ, Liu G, Wilding G, Olson BM. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clin Cancer Res. 2014;20:3692\u2013704.","journal-title":"Clin Cancer Res"},{"key":"516_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109866","volume":"9","author":"K Higashikawa","year":"2014","unstructured":"Higashikawa K, Yagi K, Watanabe K, Kamino S, Ueda M, Hiromura M, Enomoto S. 64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. PLoS One. 2014;9:e109866.","journal-title":"PLoS One"},{"key":"516_CR11","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1021\/acs.molpharmaceut.7b00056","volume":"14","author":"EB Ehlerding","year":"2017","unstructured":"Ehlerding EB, England CG, Majewski RL, Valdovinos HF, Jiang D, Liu G, McNeel DG, Nickles RJ, Cai W. ImmunoPET imaging of CTLA-4 expression in mouse models of non-small cell lung Cancer. Mol Pharm. 2017;14:1782\u20139.","journal-title":"Mol Pharm"},{"key":"516_CR12","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.7150\/thno.15253","volume":"6","author":"M Hettich","year":"2016","unstructured":"Hettich M, Braun F, Bartholom\u00e4 MD, Schirmbeck R, Niedermann G. High-resolution PET imaging with therapeutic antibody-based PD-1\/PD-L1 checkpoint tracers. Theranostics. 2016;6:1629\u201340.","journal-title":"Theranostics"},{"key":"516_CR13","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.2967\/jnumed.116.173930","volume":"57","author":"BM Larimer","year":"2016","unstructured":"Larimer BM, Wehrenberg-Klee E, Caraballo A, Mahmood U. Quantitative CD3 PET imaging predicts tumor growth response to anti-CTLA-4 therapy. J Nucl Med. 2016;57:1607\u201311.","journal-title":"J Nucl Med"},{"key":"516_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1158\/0008-5472.CAN-15-1707","volume":"76","author":"R Tavar\u00e9","year":"2016","unstructured":"Tavar\u00e9 R, Escuin-Ordinas H, Mok S, McCracken MN, Zettlitz KA, Salazar FB, Witte ON, Ribas A, Wu AM. An effective Immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy. Cancer Res. 2016;76:73\u201382.","journal-title":"Cancer Res"},{"key":"516_CR15","first-page":"371","volume":"46","author":"M Muzi","year":"2005","unstructured":"Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA. Kinetic modeling of 3\u2032-deoxy-3\u2032-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med. 2005;46:371\u201380.","journal-title":"J Nucl Med"},{"key":"516_CR16","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/3337","volume":"4","author":"AF Shields","year":"1998","unstructured":"Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334\u20136.","journal-title":"Nat Med"},{"key":"516_CR17","first-page":"274","volume":"46","author":"M Muzi","year":"2005","unstructured":"Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, Wells JM, Krohn KA. Kinetic analysis of 3\u2032-deoxy-3\u2032-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med. 2005;46:274\u201382.","journal-title":"J Nucl Med"},{"key":"516_CR18","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1007\/s00259-009-1244-4","volume":"36","author":"H Backes","year":"2009","unstructured":"Backes H, Ullrich R, Neumaier B, Kracht L, Wienhard K, Jacobs AH. Noninvasive quantification of 18F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma. Eur J Nucl Med Mol Imaging. 2009;36:1960\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"516_CR19","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2967\/jnumed.111.089482","volume":"52","author":"JS Brockenbrough","year":"2011","unstructured":"Brockenbrough JS, Souquet T, Morihara JK, Stern JE, Hawes SE, Rasey JS, Leblond A, Wiens LW, Feng Q, Grierson J, Vesselle H. Tumor 3\u2032-deoxy-3\u2032-(18)F-fluorothymidine ((18)F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of (18)F-FLT PET studies in lung tumors. J Nucl Med. 2011;52:1181\u20138.","journal-title":"J Nucl Med"},{"key":"516_CR20","doi-asserted-by":"publisher","first-page":"10104","DOI":"10.1158\/0008-5472.CAN-04-4297","volume":"65","author":"LM Kenny","year":"2005","unstructured":"Kenny LM, Vigushin DM, Al-Nahhas A, Osman S, Luthra SK, Shousha S, Coombes RC, Aboagye EO. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res. 2005;65:10104\u201312.","journal-title":"Cancer Res"},{"key":"516_CR21","doi-asserted-by":"publisher","first-page":"532","DOI":"10.2967\/jnumed.112.105999","volume":"54","author":"BA Hoeben","year":"2013","unstructured":"Hoeben BA, Troost EG, Span PN, van Herpen CM, Bussink J, Oyen WJ, Kaanders JH. 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med. 2013;54:532\u201340.","journal-title":"J Nucl Med"},{"key":"516_CR22","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1245\/s10434-011-1743-y","volume":"18","author":"K Ott","year":"2011","unstructured":"Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA, Wester HJ, Siewert JR, Zum B\u00fcschenfelde CM, Buck AK, et al. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol. 2011;18:3316\u201323.","journal-title":"Ann Surg Oncol"},{"key":"516_CR23","doi-asserted-by":"publisher","first-page":"7423","DOI":"10.1158\/1078-0432.CCR-08-0312","volume":"14","author":"HJ Sohn","year":"2008","unstructured":"Sohn HJ, Yang YJ, Ryu JS, Oh SJ, Im KC, Moon DH, Lee DH, Suh C, Lee JS, Kim SW. [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res. 2008;14:7423\u20139.","journal-title":"Clin Cancer Res"},{"key":"516_CR24","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1200\/JCO.2006.10.5825","volume":"25","author":"W Chen","year":"2007","unstructured":"Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714\u201321.","journal-title":"J Clin Oncol"},{"key":"516_CR25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s12149-012-0636-x","volume":"26","author":"ET McKinley","year":"2012","unstructured":"McKinley ET, Smith RA, Tanksley JP, Washington MK, Walker R, Coffey RJ, Manning HC. [18F]FLT-PET to predict pharmacodynamic and clinical response to cetuximab therapy in M\u00e9n\u00e9trier's disease. Ann Nucl Med. 2012;26:757\u201363.","journal-title":"Ann Nucl Med"},{"key":"516_CR26","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.2967\/jnumed.111.099200","volume":"53","author":"T Kishino","year":"2012","unstructured":"Kishino T, Hoshikawa H, Nishiyama Y, Yamamoto Y, Mori N. Usefulness of 3\u2032-deoxy-3'-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer. J Nucl Med. 2012;53:1521\u20137.","journal-title":"J Nucl Med"},{"key":"516_CR27","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1200\/JCO.2010.32.4939","volume":"29","author":"T Zander","year":"2011","unstructured":"Zander T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, Hellmich M, Papachristou I, Toepelt K, Draube A, Heukamp L, et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol. 2011;29:1701\u20138.","journal-title":"J Clin Oncol"},{"key":"516_CR28","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00259-012-2118-8","volume":"39","author":"C Kobe","year":"2012","unstructured":"Kobe C, Scheffler M, Holstein A, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Ullrich RT, Dietlein M, et al. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging. 2012;39:1117\u201327.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"516_CR29","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s00259-006-0292-2","volume":"34","author":"HA Wieder","year":"2007","unstructured":"Wieder HA, Geinitz H, Rosenberg R, Lordick F, Becker K, Stahl A, Rummeny E, Siewert JR, Schwaiger M, Stollfuss J. PET imaging with [18F]3\u2032-deoxy-3\u2032-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:878\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"516_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s12149-015-0974-6","volume":"29","author":"ET McKinley","year":"2015","unstructured":"McKinley ET, Watchmaker JM, Chakravarthy AB, Meyerhardt JA, Engelman JA, Walker RC, Washington MK, Coffey RJ, Manning HC. [(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study. Ann Nucl Med. 2015;29:535\u201342.","journal-title":"Ann Nucl Med"},{"key":"516_CR31","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1007\/s12149-014-0902-1","volume":"28","author":"H Hoshikawa","year":"2014","unstructured":"Hoshikawa H, Yamamoto Y, Mori T, Kishino T, Fukumura T, Samukawa Y, Mori N, Nishiyama Y. Predictive value of SUV-based parameters derived from pre-treatment (18)F-FLT PET\/CT for short-term outcome with head and neck cancers. Ann Nucl Med. 2014;28:1020\u20136.","journal-title":"Ann Nucl Med"},{"key":"516_CR32","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.18632\/oncotarget.1990","volume":"5","author":"K Herrmann","year":"2014","unstructured":"Herrmann K, Buck AK, Schuster T, Abbrederis K, Bl\u00fcmel C, Santi I, Rudelius M, Wester HJ, Peschel C, Schwaiger M, et al. Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL. Oncotarget. 2014;5:4050\u20139.","journal-title":"Oncotarget"},{"key":"516_CR33","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00259-015-3000-2","volume":"42","author":"A Challapalli","year":"2015","unstructured":"Challapalli A, Barwick T, Pearson RA, Merchant S, Mauri F, Howell EC, Sumpter K, Maxwell RJ, Aboagye EO, Sharma R. 3\u2032-Deoxy-3'-18F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer. Eur J Nucl Med Mol Imaging. 2015;42:831\u201340.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"516_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12149-012-0652-x","volume":"27","author":"M Inubushi","year":"2013","unstructured":"Inubushi M, Saga T, Koizumi M, Takagi R, Hasegawa A, Koto M, Wakatuki M, Morikawa T, Yoshikawa K, Tanimoto K, et al. Predictive value of 3\u2032-deoxy-3\u2032-[18F]fluorothymidine positron emission tomography\/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma. Ann Nucl Med. 2013;27:1\u201310.","journal-title":"Ann Nucl Med"},{"key":"516_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejca.2015.11.018","volume":"55","author":"VR Bollineni","year":"2016","unstructured":"Bollineni VR, Kramer GM, Jansma EP, Liu Y, Oyen WJ. A systematic review on [(18)F]FLT-PET uptake as a measure of treatment response in cancer patients. Eur J Cancer. 2016;55:81\u201397.","journal-title":"Eur J Cancer"},{"key":"516_CR36","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2967\/jnumed.109.070946","volume":"51","author":"A Ribas","year":"2010","unstructured":"Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med. 2010;51:340\u20136.","journal-title":"J Nucl Med"},{"key":"516_CR37","doi-asserted-by":"publisher","first-page":"18396","DOI":"10.1073\/pnas.1113045108","volume":"108","author":"EH Aarntzen","year":"2011","unstructured":"Aarntzen EH, Srinivas M, De Wilt JH, Jacobs JF, Lesterhuis WJ, Windhorst AD, Troost EG, Bonenkamp JJ, van Rossum MM, Blokx WA, et al. Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3\u2032-fluoro-3\u2032-deoxy-thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci U S A. 2011;108:18396\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"516_CR38","doi-asserted-by":"publisher","first-page":"25586","DOI":"10.18632\/oncotarget.25387","volume":"9","author":"DG McNeel","year":"2018","unstructured":"McNeel DG, Eickhoff JC, Wargowski E, Zahm C, Staab MJ, Straus J, Liu G. Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 2018;9:25586\u201396.","journal-title":"Oncotarget"},{"key":"516_CR39","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1158\/2326-6066.CIR-14-0206","volume":"3","author":"BT Rekoske","year":"2015","unstructured":"Rekoske BT, Smith HA, Olson BM, Maricque BB, McNeel DG. PD-1 or PD-L1 blockade restores antitumor efficacy following SSX2 epitope-modified DNA vaccine immunization. Cancer Immunol Res. 2015;3:946\u201355.","journal-title":"Cancer Immunol Res"},{"key":"516_CR40","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1158\/2326-6066.CIR-16-0374","volume":"5","author":"CD Zahm","year":"2017","unstructured":"Zahm CD, Colluru VT, McNeel DG. Vaccination with high-affinity epitopes impairs antitumor efficacy by increasing PD-1 expression on CD8. Cancer Immunol Res. 2017;5:630\u201341.","journal-title":"Cancer Immunol Res"},{"key":"516_CR41","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate Cancer clinical trials working group. J Clin Oncol. 2008;26:1148\u201359.","journal-title":"J Clin Oncol"},{"key":"516_CR42","first-page":"1431","volume":"45","author":"JA Thie","year":"2004","unstructured":"Thie JA. Understanding the standardized uptake value, its methods and implications for usage. J Nucl Med. 2004;45:1431\u20134.","journal-title":"J Nucl Med"},{"key":"516_CR43","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/aaa175","volume":"63","author":"M Scarpelli","year":"2018","unstructured":"Scarpelli M, Eickhoff J, Cuna E, Perlman S, Jeraj R. Optimal transformations leading to normal distributions of positron emission tomography standardized uptake values. Phys Med Biol. 2018;63:035021.","journal-title":"Phys Med Biol"},{"key":"516_CR44","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1093\/bioinformatics\/btr511","volume":"27","author":"MS Schr\u00f6der","year":"2011","unstructured":"Schr\u00f6der MS, Culhane AC, Quackenbush J, Haibe-Kains B. Survcomp: an R\/Bioconductor package for performance assessment and comparison of survival models. Bioinformatics. 2011;27:3206\u20138.","journal-title":"Bioinformatics"},{"key":"516_CR45","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1002\/sim.1802","volume":"23","author":"MJ Pencina","year":"2004","unstructured":"Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23:2109\u201323.","journal-title":"Stat Med"},{"key":"516_CR46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, M\u00fcller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.","journal-title":"BMC Bioinformatics"},{"key":"516_CR47","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"516_CR48","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28:583\u20139.","journal-title":"Ann Oncol"},{"key":"516_CR49","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"key":"516_CR50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0516-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T12:35:14Z","timestamp":1606307714000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0516-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["516"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0516-1","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,30]]},"assertion":[{"value":"6 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol for this study was reviewed and approved by all local (University of Wisconsin Human Subjects\u2019 Review Board (IRB). All patients gave written informed consent for participation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Douglas G. McNeel has ownership interest, has received research support, and serves as consultant to Madison Vaccines, Inc. which has licensed intellectual property related to this content. None of the other authors have relevant potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"23"}}